Accessibility Menu
Microbix Biosystems logo

Microbix Biosystems(OTC) MBXBF

Market Cap$30.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-26%
5 Year-56%
1 Year+3%
1 Month+5%
$0.22
+0%
+0.00Today
Microbix Biosystems last closing stock price
MetricPriceDate
Last closeUSD 0.222026-07-27
Microbix Biosystems stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.04%USD 0.212026-07-16
1 month+4.76%USD 0.212026-06-25
3 month+25.71%USD 0.182026-04-20
Year to date+26.36%USD 0.172025-12-30
1 year+2.9%USD 0.212025-07-24
3 year-8.33%USD 0.242023-07-28
5 year-55.7%USD 0.502021-07-28
Since inception-26.3%USD 0.302012-06-08

Microbix Biosystems Financials at a Glance

Market Cap

$30.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$14.82M

Net Income (TTM)

-CA$5.24M

EPS (TTM)

-$0.03

P/E Ratio

-7.41

Dividend

$0.00

Beta (Volatility)

0.09 (Low)

Price

$0.22

Volume

1,000

Open

$0.22

Previous Close

$0.22

Daily Range

$0.22 - $0.22

52-Week Range

$0.15 - $0.23

Estimated Earnings Date

Aug 13, 2026

MBXBF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Microbix Biosystems

Microbix Biosystems Inc. is a life sciences company focused on developing and marketing innovative biological products aimed at enhancing human health. The company specializes in producing essential biological reagents for the diagnostics industry, including antigens and proprietary Quality Assessment and Proficiency (QAP) products.

Products and Services
  • Biological reagents for diagnostics, including antigens for immunoassays
  • Quality Assessment and Proficiency (QAP) products for clinical laboratories
  • Specialized products like DxTM for viral transport and Kinlytic Urokinase for blood clots
Growth Outlook
  • Recent revenue of CAD 3.39 million indicates a strong market presence
  • Gross profit margin improved to 48.2% in the latest quarter
  • Expansion into international markets supports long-term growth potential
Financial Highlights
  • Trailing twelve months (TTM) revenue of CAD 14.1 million reflects consistent demand
  • Current ratio of 5.35 suggests strong liquidity and financial health
  • Net income margin of -38.6% indicates room for operational improvements
Microbix Biosystems Inc. operates in the biotechnology sector, providing critical products that support diagnostic testing and laboratory proficiency. The company has established a solid foundation with its innovative offerings, which are essential for clinical laboratories and diagnostic firms. Recent financial performance shows promising revenue growth, with a notable gross profit margin, indicating effective cost management and product demand. The company's strong liquidity position, as evidenced by a current ratio of 5.35, allows for flexibility in operations and potential investments in growth initiatives. Despite facing challenges reflected in the net income margin, the ongoing expansion into international markets and the focus on enhancing product offerings position Microbix for future success.
AI Generated • Jun 30, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Cameron L. Groome

Website

microbix.com

Headquarters

Mississauga, ON L4Z 1P3, CA

MBXBF Financials

Key Financial Metrics (TTM)

Gross Margin

42.49%

Operating Margin

-33.32%

Net Income Margin

-38.62%

Return on Equity

-21.02%

Return on Capital

-4.39%

Return on Assets

-16.18%

Earnings Yield

-13.50%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$30.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

137.50M

Volume

1.00K

Avg. Volume

8.72K

Financials (TTM)

Gross Profit

CA$6.30M

Operating Income

-CA$5.07M

EBITDA

-CA$3.27M

Operating Cash Flow

-CA$4.75M

Capital Expenditure

-CA$742.61K

Free Cash Flow

-CA$5.49M

Cash & ST Invst.

CA$8.15M

Total Debt

CA$6.81M

Microbix Biosystems Performance Analysis

Microbix Biosystems annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-09-30CAD 14,931,1281.6%
20232023-09-30CAD 12,244,253-18.0%
20242024-09-30CAD 18,661,00252.4%
20252025-09-30CAD 13,292,966-28.8%
Microbix Biosystems sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-06-30-34.8%
Q42025-09-308.0%
Q12025-12-3112.4%
Q22026-03-31-19.7%
Microbix Biosystems annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-09-30CAD 0.01-51.9%
20232023-09-30CAD -0.00N/A
20242024-09-30CAD 0.02N/A
20252025-09-30CAD -0.01N/A
Microbix Biosystems sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-06-30-12100.0%
Q42025-09-3011.7%
Q12025-12-3120.8%
Q22026-03-31-22.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$3.39M

-36.4%

Gross Profit

CA$1.63M

-48.5%

Gross Margin

48.20%

N/A

Market Cap

$30.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$302.50K

N/A

Employees

100

N/A

Net Income

-CA$1.43M

-7039.8%

EBITDA

-CA$800.91K

-214.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$8.15M

-43.9%

Total Debt

CA$6.81M

+27.3%

Accounts Receivable

CA$3.27M

+30.1%

Inventory

CA$10.10M

+22.1%

Long Term Debt

CA$5.87M

+11.8%

Short Term Debt

CA$941.46K

+861.9%

Return on Assets

-16.18%

N/A

Return on Invested Capital

-15.80%

N/A

Free Cash Flow

-CA$531.77K

-173.7%

Operating Cash Flow

-CA$308.57K

-131.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PVCTProvectus Biopharmaceuticals, Inc.
$0.06-0.17%
DTCFFDefence Therapeutics Inc.
$0.29+9.96%
RVXCFResverlogix Corp.
$0.07-11.04%
FNCHFinch Therapeutics Group, Inc.
$9.60-3.71%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.20-0.01%
NOKNokia
$8.91-0.04%
JBLUJetBlue Airways
$6.00+0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.12-0.02%

Questions About MBXBF

What is the current price of Microbix Biosystems?

Microbix Biosystems is trading at $0.22 per share.

What is the 52-week range for Microbix Biosystems?

Over the past 52 weeks, Microbix Biosystems has traded between $0.15 and $0.23.

How much debt does Microbix Biosystems have?

As of the most recent reporting period, Microbix Biosystems reported total debt of CA$4.87M.

How much cash does Microbix Biosystems have on hand?

Microbix Biosystems reported CA$5.83M in cash and cash equivalents in its most recent financial results.

What is Microbix Biosystems’s dividend yield?

Microbix Biosystems does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services